Earnings Call · Q3 FY2023·2023-11-07

Q3 23EPS -18.75%·Rev n/aQ2 23EPS -22.73%·Rev n/aQ1 23EPS -4.46%·Rev n/aQ4 22EPS +28.89%·Rev n/a⚠ consensus missing

NEKTAR THERAPEUTICS NKTR

Vivian Wu — Unknown

Howard Robin — President and CEO

Jonathan Zalevsky — Chief of Research and Development

Mary Tagliaferri — Chief Medical Officer

Jennifer Ruddock — Chief Business Officer

+3.4%1d on move date+3.2% vs SPY3d−10.3%5d−15.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NKTR calls or request research access.

More NKTR calls Browse calls Request research access